小智港股覆盤 | 4月1日
今日，港股三大指數漲跌互現。截止收盤，恆生指數漲0.19%，報22039點。國企指數漲0.15%，報7537點。恆生科技指數跌0.74%，報4524點。市場約883只個股上漲，811只個股下跌。成交額突破946.0億港幣，和昨天同期相比下跌7.61%。
盤面上，海運板塊全線走強。中遠海控漲超9%；海豐國際、太平洋航運等多股漲超5%；東方海外國際漲超4%；金輝集團漲超3%。交銀國際維持中遠海控買入評級，目標價續看15.7港元；東方海外國際全年股東應佔溢利71.28億美元，同比增長689.63%，擬派末期息2.61元；金輝集團附屬擬2550萬美元購入一艘散裝貨船。
居家用品板塊大漲靠前。維達國際漲超4%；藍月亮集團漲超3%。藍月亮集團發佈2021年業績，收益75.97億港元，同比增長8.59%，末期息每股13.8港仙。
個人用品板塊走高。中智藥業漲超10%；恆安國際漲超3%；L'OCCITANE漲超2%；明輝國際漲超1%。中智藥業獲主席兼執董賴智填增持46萬股。
食品零售板塊多數下跌。力寶華潤跌超9%；聯華超市跌超6%；高鑫零售跌超5%；利特米、利亞零售等多股跌超3%。力寶華潤扭虧全年賺4,867萬元，末期息派0.45仙；聯華超市發佈2021年業績，年度股東應佔虧損4.23億元，同比增32%；利特米全年純利1,184萬令吉增40%，不派息；利亞零售獲非執行董事馮國綸增持300萬股。
互聯網醫療板塊走低。平安好醫生跌超3%；阿裏健康跌超2%；醫渡科技跌超1%。平安好醫生3月30日耗資1029.78萬港元回購49萬股。
生物科技板塊走低。雲頂新耀-B、嘉和生物-B等多股跌超11%；科濟藥業-B跌超8%；康方生物-B、永泰生物-B等多股跌超6%。雲頂新耀－B去年虧損收窄至10.09億元人民幣，不派末期息；嘉和生物-B公佈年度業績，研發開支達6.13億元，將聚焦潛在FIC/BIC創新管線；康方生物-B公佈年度業績，產品及許可費總銷售額3.4億元，研發開支達11.23億元；永泰生物-B公佈年度業績，研發開支達2.41億元，擬擴大戰略合作及發掘併購機遇。
uSMART智能寫手的信息、數據均來自媒體公開報道，智能寫手不能保證其完全準確，內容僅供參考，不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
